Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Gugliotta G, et al. Among authors: marzocchi g. Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30. Blood. 2011. PMID: 21450900 Free article.
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. Soverini S, et al. Among authors: marzocchi g. J Clin Oncol. 2006 Nov 20;24(33):e51-2. doi: 10.1200/JCO.2006.08.9128. J Clin Oncol. 2006. PMID: 17114651 No abstract available.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: marzocchi g. Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822. Haematologica. 2007. PMID: 17339191 Free article. Clinical Trial.
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia. Palandri F, et al. Among authors: marzocchi g. Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838477 Free article. Clinical Trial.
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Among authors: marzocchi g. Leuk Lymphoma. 2009 Jan;50(1):114-8. doi: 10.1080/10428190802492415. Leuk Lymphoma. 2009. PMID: 19125382 No abstract available.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11. Blood. 2009. PMID: 19211938 Free article. Clinical Trial.
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Baldazzi C, Luatti S, Marzocchi G, Stacchini M, Gamberini C, Castagnetti F, Palandri F, Rosti G, Baccarani M, Testoni N. Baldazzi C, et al. Among authors: marzocchi g. Leuk Res. 2009 Dec;33(12):e218-20. doi: 10.1016/j.leukres.2009.05.010. Epub 2009 Jun 13. Leuk Res. 2009. PMID: 19525008 No abstract available.
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.
Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M. Testoni N, et al. Among authors: marzocchi g. Blood. 2009 Dec 3;114(24):4939-43. doi: 10.1182/blood-2009-07-229864. Epub 2009 Oct 1. Blood. 2009. PMID: 19797518 Free article.
103 results